Treatment-related adverse events
| TRAEs . | n (%) for overall population, N = 210 . |
|---|---|
| Any-grade TRAE | 153 (72.9) |
| TRAEs ≥5% | |
| Hypothyroidism | 30 (14.3) |
| Pyrexia | 24 (11.4) |
| Fatigue | 23 (11.0) |
| Rash | 23 (11.0) |
| Diarrhea | 17 (8.1) |
| Headache | 16 (7.6) |
| Nausea | 15 (7.1) |
| Arthralgia | 13 (6.2) |
| Cough | 13 (6.2) |
| Pruritus | 13 (6.2) |
| Infusion-related reaction | 11 (5.2) |
| Neutropenia | 11 (5.2) |
| Grade 3 or 4 TRAEs | 27 (12.9) |
| Grade 3 or 4 TRAEs in ≥2 patients | |
| Neutropenia | 5 (2.4) |
| Pericarditis | 2 (1.0) |
| Diarrhea | 2 (1.0) |
| TRAEs . | n (%) for overall population, N = 210 . |
|---|---|
| Any-grade TRAE | 153 (72.9) |
| TRAEs ≥5% | |
| Hypothyroidism | 30 (14.3) |
| Pyrexia | 24 (11.4) |
| Fatigue | 23 (11.0) |
| Rash | 23 (11.0) |
| Diarrhea | 17 (8.1) |
| Headache | 16 (7.6) |
| Nausea | 15 (7.1) |
| Arthralgia | 13 (6.2) |
| Cough | 13 (6.2) |
| Pruritus | 13 (6.2) |
| Infusion-related reaction | 11 (5.2) |
| Neutropenia | 11 (5.2) |
| Grade 3 or 4 TRAEs | 27 (12.9) |
| Grade 3 or 4 TRAEs in ≥2 patients | |
| Neutropenia | 5 (2.4) |
| Pericarditis | 2 (1.0) |
| Diarrhea | 2 (1.0) |
TRAE, treatment–related adverse event.